Article
Biochemistry & Molecular Biology
Xiaohui Si, Lu Xiao, Christine E. Brown, Dongrui Wang
Summary: This review provides an overview of the development of in vitro and in vivo models for evaluating CAR T cell function, and discusses how these models can provide information for the preclinical assessment of CAR T cell therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Bradley J. Monk, Nicoletta Colombo, Amit M. Oza, Keiichi Fujiwara, Michael J. Birrer, Leslie Randall, Elena Poddubskaya, Giovanni Scambia, Yaroslav Shparyk, Myong Cheol Lim, Snehalkumar M. Bhoola, Joohyuk Sohn, Kan Yonemori, Ross A. Stewart, Xiaoxi Zhang, Julia Perkins Smith, Carlos Linn, Jonathan A. Ledermann
Summary: The JAVELIN Ovarian 100 trial compared the efficacy of avelumab in combination with chemotherapy followed by avelumab maintenance, avelumab plus chemotherapy followed by avelumab maintenance, or chemotherapy alone in treatment-naive epithelial ovarian cancer patients. Results showed that avelumab did not demonstrate significant benefits in frontline treatment, suggesting the need for alternative treatment regimens to improve outcomes in advanced epithelial ovarian cancer patients.
Article
Chemistry, Multidisciplinary
Sagang Koo, Ok Kyu Park, Jonghoon Kim, Sang Ihn Han, Tae Yong Yoo, Nohyun Lee, Young Geon Kim, Hyunjoong Kim, Chaehong Lim, Jong-Seong Bae, Jin Yoo, Dokyoon Kim, Seung Hong Choi, Taeghwan Hyeon
Summary: The study presents a heterogeneous chemodynamic therapy (CDT) system based on copper-iron peroxide nanoparticles for synergistic therapy in the tumor microenvironment (TME). The system demonstrates excellent tumor therapeutic efficacy by enhancing hydroxyl radical production through a highly efficient catalytic loop. It also generates O-2 and exhibits TME-responsive T-1 magnetic resonance imaging contrast enhancement.
Article
Nanoscience & Nanotechnology
X. Shi, L. Shu, Y. Qiao, J. Yao, H. Xie, L. Zhou, H. Wang, S. Zheng
Summary: STAT3 is a key converging point of multiple oncogenic pathways and is constitutively activated in various cancer cells. Stattic, a selective inhibitor of STAT3, has shown promising potential for targeted cancer therapy and has been formulated in nanoparticles to enhance its therapeutic effects against tumor growth and metastasis.
MATERIALS TODAY NANO
(2022)
Article
Oncology
Isabel Quiros-Gonzalez, Michal R. Tomaszewski, Monika A. Golinska, Emma Brown, Laura Ansel-Bollepalli, Lina Hacker, Dominique-Laurent Couturier, Rosa M. Sainz, Sarah E. Bohndiek
Summary: The study suggests that photoacoustic tomography may provide an early indication of response or resistance to antiangiogenic therapy, clearly distinguishing between control, responding, and resistant tumors within just a few weeks of treatment.
Review
Biotechnology & Applied Microbiology
Xiaoyong Guan, Shigao Huang
Summary: Traditional tumor models are unable to accurately simulate the real state of tumors in vivo, leading to the termination of many clinical trials. However, 3D tumor models' technology offers new in vitro models that bridge the gap between in vitro and in vivo findings. Organoids, in particular, can maintain the properties of the original tissue over a long period of culture, enabling extensive research and serving as potential substitutes for animal and in vitro models. 3D tumor models also provide a promising platform for high-throughput research, drug testing, disease modeling, and regenerative medicine.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Oncology
Sonia A. Patel, Matthew H. Herynk, Tina Cascone, Babita Saigal, Monique B. Nilsson, Hai Tran, Sumankalai Ramachandran, Lixia Diao, Jing Wang, Xiuning Le, John Minna, Ignacio I. Wistuba, John V. Heymach
Summary: Subgroup analyses suggest that females may derive less benefit from VEGF monoclonal antibody bevacizumab than males in treating metastatic NSCLC. Estrogen may promote resistance to VEGF-targeted therapies by enhancing pericyte coverage and myeloid recruitment. Blockade of the estrogen receptor pathway could potentially enhance the effects of antiangiogenic therapy.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Ani Georgieva, Katerina Todorova, Ivan Iliev, Valeria Dilcheva, Ivelin Vladov, Svetlozara Petkova, Aleksandar Dolashki, Lyudmila Velkova, Pavlina Dolashka, Reneta Toshkova
Summary: This study aims to assess the anticancer activity of hemocyanins isolated from Helix aspersa, Helix lucorum, and Rapana venosa in the Graffi myeloid tumor model. The results showed that the tested hemocyanins exhibited significant antiproliferative and apoptogenic effects in vitro, as well as a protective antitumor effect in vivo, without any toxic side effects.
Article
Pharmacology & Pharmacy
Jin-Man Zhang, Yao-Yao Jiang, Qun-Fa Huang, Xu-Xiu Lu, Guan-Hai Wang, Chang-Lun Shao, Ming Liu
Summary: This study encapsulated the macrolide brefeldin A (BFA) in mixed nanomicelles to improve its solubility, stability, and sustained release capability. M-BFA showed significant inhibitory effects on HepG2 liver carcinoma cells in vitro, inducing cell cycle arrest, apoptosis, and autophagic cell death. In a HepG2 tumor-bearing xenograft mouse model, M-BFA effectively delayed tumor progression and induced extensive necrosis. These findings suggest the promising potential of M-BFA in therapy for hepatocellular carcinoma.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Immunology
Melanie Demeules, Allan Scarpitta, Romain Hardet, Henri Gonde, Catalina Abad, Marine Blandin, Stephan Menzel, Yinghui Duan, Bjoern Rissiek, Tim Magnus, Anna Marei Mann, Friedrich Koch-Nolte, Sahil Adriouch
Summary: Adenosine triphosphate (ATP) is a danger signal that accumulates in injured tissues, inflammatory sites, and the tumor microenvironment. It promotes tumor growth and anti-tumor immune responses via the P2X7 receptor. P2X7, CD39, and CD73 are novel purinergic checkpoints that can be targeted for cancer treatment. Blocking P2X7 inhibits tumor growth, while a nanobody-based biologic targeting P2X7 enhances tumor control and immune responses when used in combination with chemotherapy. A bi-specific nanobody-based biologic targeting PD-L1 and CD73 has a potent anti-tumor effect.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Keisuke Yokohama, Hiroki Nishikawa, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Takashi Kumada
Summary: This study aimed to evaluate the ability of a TM score involving AFP, AFP-L3, and DCP to predict the prognosis and therapeutic efficacy in HCC patients treated with Atez/Bev. The results showed that the TM score was useful in predicting the overall survival (OS) and progression-free survival (PFS) in these patients. The mALBI grade was also a good predictor of OS and PFS.
Article
Medicine, General & Internal
Joana Heinzelmann, Sabine Hecht, Alexander Ruben Vogt, Udo Siebolts, Peter Kaatzsch, Arne Viestenz
Summary: The study demonstrates the improved effectiveness of repetitive electrochemotherapy (ECT) on conjunctival melanoma (CM) by reducing tumor size, inhibiting proliferation, inducing apoptosis, and decreasing the percentage of surviving tumor cells. Repetitive ECT could be an alternative therapy option for CM.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Marcel A. Heinrich, Ahmed M. R. H. Mostafa, Jennifer P. Morton, Lukas J. A. C. Hawinkels, Jai Prakash
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer type with a complex tumor microenvironment, making treatment challenging. This article provides an overview of recent developments in in vitro and in vivo models aiming to mimic the complexity of PDAC, highlighting the lack of biologically relevant models that resemble the complexity of PDAC.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Article
Immunology
Jinrong He, Peng Zheng, Yongjun Chen, Jialong Qi, Chao Ye, Duo Li, Ying Yang, Qingwen Liu, Yongmao Hu, Xiao Zheng, Weiran Li, Liangqun Hua, Zhongqian Yang, Haoqian Chen, Weiwei Huang, Wenjia Sun, Xu Yang, Qiong Long, Hongmei Bai, Yanbing Ma
Summary: This study explores the potential application of inducing tumor cell pyroptosis to promote anti-tumor immunity and achieves significant suppression of tumor growth in mice.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Xiaomin Jiang, Morten Lee, Junjie Xia, Taokun Luo, Jianqiao Liu, Megan Rodriguez, Wenbin Lin
Summary: This study reports a two-stage release strategy to effectively deliver oxaliplatin and SN38 chemotherapy drugs to tumors using nanoparticles, reducing general toxicity. Compared to other chemotherapy drugs, this strategy can decrease the exposure of SN38 in the blood and increase exposure in tumors. The results show that these nanoparticles have a significant inhibitory effect on tumors in vivo without causing side effects. Furthermore, the study also found that the nanoparticles can enhance immunogenic cell death and promote tumor immune response. This research highlights the potential of combining prodrug design and nanomedicine formulation.